Tel Aviv, Israel and Parsippany, New Jersey--(BUSINESS WIRE)--(BUSINESS WIRE)--Teva Pharmaceuticals, the U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the The United States launched the first available generic version, THIOLA® (Tiopronin) tablets, showing that, combined with high fluid intake, alkali and dietary adjustments, it is used to prevent adults and 9 years and older with severe homozygous cystamine Cystine (kidney) stones are formed in children with aciduria, who cannot respond to these measures alone.

"Teva is pleased to provide patients with the first marketed universal version of THIOLA® (Tiopronin) tablets for the prevention of kidney stones and patients who do not respond to high fluid intake, alkali and dietary treatments," Teva Said Christine Baeder, senior vice president and chief operating officer of American Generics.

Teva has nearly 550 generic drugs, has the largest FDA-approved generic drug product portfolio on the market, and is a leader in first-time application opportunities. There are approximately 100 pending first-time applications in the United States. Currently, 1 is in the United States The 11 generic drug prescriptions dispensed contained Teva generic drugs.

Tiopronin tablets are a prescription drug that, in combination with high fluid intake, alkalinity (low acid), and dietary changes, helps prevent certain adults and children aged 9 years or older from forming a (cystine) kidney stone. Do not respond to these measures alone.

Who should not take Tiopronin tablets? If you are allergic to tiopronin or any of the ingredients in tiopronin tablets, you should not take tiopronin tablets.

What should I tell my doctor before taking tiopronin tablets? Before taking tiopronin tablets, tell your doctor:

What are the possible side effects of Tiopronin tablets? Tiopronin tablets can cause proteinuria (a lot of protein in the urine), including severe kidney problems and allergic reactions (including fever, rash, joint pain, and swelling or swelling of lymph nodes).

The most common side effects of tiopronin tablets include nausea, diarrhea or soft stools, mouth ulcers, skin rash, fatigue, fever, muscle or joint pain, high protein content in the urine, and vomiting.

These are not all the possible side effects of Tiopronin tablets. For more information, please consult your doctor or pharmacist.

For more information, please refer to the enclosed prescribing information. You can call 888-TEVA-USA (888-838-2872), druginfo@tevapharm.com or Teva's public relations or investor relations contact to request a copy from the Teva U.S. Department of Medical Information.

For more than a century, Teva Pharmaceutical Industries Co., Ltd. (NYSE code and TASE code: TEVA) has been committed to the development and production of drugs that improve people’s lives. We are a global leader in generics and specialty drugs, and our product portfolio includes more than 3,500 products in almost all therapeutic areas. Approximately 200 million people around the world take Teva drugs every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. In addition to our solid position in the generic drug field, we also have important innovative research and operations to support our growing portfolio of specialty and biopharmaceutical products. Learn more on www.tevapharm.com.

Note on forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch of our 100-mg-strength universal version of THIOLA® (Tiopronin) tablets in the United States. These statements are based on management’s current beliefs and expectations. Subject to known and unknown major risks and uncertainties, these risks and uncertainties may cause our future results, performance or achievements to be significantly different from those expressed or implied by such forward-looking statements. Important factors that may cause or contribute to such differences include risks related to:

Other factors discussed in this press release and in our annual report on Form 10-K for the year ended December 31, 2020, including the sections titled "Risk Factors" and "Forward-Looking Statements." Forward-looking statements are only published on the date they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether due to new information, future events or other reasons. You are warned not to rely too much on these forward-looking statements.

_________________ 1 THIOLA EC® is a registered trademark of Mission Pharmacal.

IR Contact United States Kevin C. Mannix (215) 591-8912 Israel Yael Ashman 972 (3) 914-8262

Public Relations Contact United States Kelley Dougherty (973) 658-0237 Israel Yonatan Beker 972 (54) 888 5898

Teva announces the launch of the first universal version of THIOLA® (Tiopronin) tablets in the United States

IR Contact United States Kevin C. Mannix (215) 591-8912 Israel Yael Ashman 972 (3) 914-8262

Public Relations Contact United States Kelley Dougherty (973) 658-0237 Israel Yonatan Beker 972 (54) 888 5898